December 13, 2023 03:41 PM EST
Pharma

PwC pre­dicts ac­tive 2024 for phar­ma deals as M&A val­ue climbs

Nicole DeFeudis

Editor

PwC has de­clared 2023 a “rea­son­ably strong year” for M&A in the phar­ma­ceu­ti­cal and life sci­ences sec­tor, de­spite a slight dip in over­all deal vol­ume …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

‘Just the be­gin­ning’: No­bel Prizes show the AI era has ar­rived in biotech

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

A service from the Financial Times